
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Safinamide, a medication having many mechanisms of action, is used as an additional therapy for Parkinson's disease with "off" episodes. One of these mechanisms is the inhibition of monoamine oxidase B.
Levodopa/carbidopa and safinamide are combined to treat the symptoms of Parkinson's disease. It can aid in alleviating symptoms like trembling, stiffness, and difficulty moving.
Additionally, it may aid in minimising "off" time (periods of slow movement or stiffness). Safinamide is a member of the MAO inhibitor drug subclass.
It functions by raising the concentrations of specific natural chemicals in the brain (such as dopamine). Too little dopamine in the brain is assumed to be the cause of Parkinson's disease.
If you have any allergies, including to safinamide, make sure to let your doctor or pharmacist know before taking any medication. Inactive chemicals in this product have the potential to trigger allergic reactions or other issues.
People with significant liver impairment, albinism, retinitis pigmentosa, severe diabetic neuropathy, uveitis, and other retinal problems should not take safinamide. Pethidine and other monoamine oxidase (MAO) inhibitors should not be combined.
Nausea, vertigo, exhaustion, insomnia, orthostatic hypotension (low blood pressure), and headache were common side effects in clinical trials (in greater than 1% of participants). Between safinamide and placebo, there was no discernible difference in the frequency of these side events.
Global SAFINAMIDE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Safinamide, also known by the brand name Xadago, was introduced by Zambon and its business partner Newron Pharmaceuticals in the UK.
Safinamide enhanced quality of life and mood while reducing "off" periodsâwhen medication stops workingâwithout raising the risk of dyskinesia.
Safinamide is an MAO-B inhibitor and, like other drugs already in use, stops the enzyme monoamine oxidase type B (MAO-B) from degrading dopamine.
This new medication, however, inhibits the MAO-B enzyme in a slightly different manner, which might increase its efficacy in the treatment of Parkinson's.
Safinamide serves the same purpose as certain already available Parkinson's medications, therefore your doctor will only recommend it when necessary.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |